中文版
ChemBest-Your Best Partner-Reliable And Trustworthy!
Home > Products SHARE THIS:
Panobinostat
Product Number :
CL2002
Product Name :
Panobinostat
CAS No. :
404950-80-7
Synonyms :
LBH589; NVP-LBH589
Chemical Name :
Molecular Formula :
C21H23N3O2
Molecular Weight :
349.43
Molecular Structure :
Appearance :
Light brown powder
Specification :
98+%
Application :
Registration :
Storage Condition :

Panobinostat, also known as NVP LBH-589 or LBH-589, is a cinnamic hydroxamic acid analogue with potential antineoplastic activity. Panobinostat selectively inhibits histone deacetylase (HDAC), inducing hyperacetylation of core histone proteins, which may result in modulation of cell cycle protein expression, cell cycle arrest in the G2/M phase and apoptosis. In addition, this agent appears to modulate the expression of angiogenesis-related genes, such as hypoxia-inducible factor-1alpha (HIF-1a) and vascular endothelial growth factor (VEGF), thus impairing endothelial cell chemotaxis and invasion. On 2/23/2015, it received FDA accelerated approval for use in patients with multiple myeloma who had received at least 2 previous treatments, including bortezomib and an immunomodulatory agent.

Statement:
->>Products covered by valid patents are not offered or supplied for commercial use.
->>Products currently covered by valid US Patents are offered for laboratory R&D use in accordance with 35 USC 271(e)+A13(1).
->>Any patent infringement and resulting liability is solely at buyer's risk.
->>Our products are only raw materials for drugs or industry, can't be used for human or animals directly.

  • Panobinostat, also known as NVP LBH-589 or LBH-589, is a cinnamic hydroxamic acid analogue with potential antineoplastic activity. Panobinostat selectively inhibits histone deacetylase (HDAC), inducing hyperacetylation of core histone proteins, which may result in modulation of cell cycle protein expression, cell cycle arrest in the G2/M phase and apoptosis. In addition, this agent appears to modulate the expression of angiogenesis-related genes, such as hypoxia-inducible factor-1alpha (HIF-1a) and vascular endothelial growth factor (VEGF), thus impairing endothelial cell chemotaxis and invasion. On 2/23/2015, it received FDA accelerated approval for use in patients with multiple myeloma who had received at least 2 previous treatments, including bortezomib and an immunomodulatory agent.
  • Capsiate

    Ansamitocin P-3

    Verteporfin

    Brefeldin A

    ICG-001

    Temoporfin

    Y-27632 Dihydrochloride

    Resatorvid (TAK-242)

    Cobimetinib (GDC-0973)

    GSK-690693

    GSK2193874

    AICAR (Acadesine)

Request A Quote
Your Name(required)
Email(required)
Product Name(required)
Country or Region(required)
Organization Name(required)
Messages(required)
Captcha(required)
Sending...

Products

By Alphabetical Product Index:
By CAS No.: